Cilofexor
- Generic Name
- Cilofexor
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22Cl3N3O5
- CAS Number
- 1418274-28-8
- Unique Ingredient Identifier
- YUN2306954
- Background
Cilofexor is under investigation in clinical trial NCT02943447 (Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 11
- Registration Number
- NCT04060147
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
🇺🇸University of California San Francisco, Liver Clinic, San Francisco, California, United States
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 109
- Registration Number
- NCT03987074
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Institute for Liver Health - Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Quality Medical Research, PLLC, Nashville, Tennessee, United States
Study of Cilofexor in Adults With Primary Sclerosing Cholangitis
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 419
- Registration Number
- NCT03890120
- Locations
- 🇺🇸
Texas Clinical Research Institute, Arlington, Texas, United States
🇺🇸Ruane Clinical Research Group Inc., Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 71
- Registration Number
- NCT02943447
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT02943460
- Locations
- 🇺🇸
The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇦🇹Universitätsklinik Klinik für Innere Medizin III, Vienna, Austria
🇨🇦University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary, Alberta, Canada
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT02808312
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics
- Conditions
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT02654002
- Locations
- 🇺🇸
SeaView Research, Inc, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.